![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
1. 1201186-54-0
2. N-tosyl-5-bromo-4,7-diazaindole
3. 2-bromo-5-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyrazine
4. Mfcd12964053
5. 2-bromo-5-(p-tolylsulfonyl)-5h-pyrrolo[2,3-b]pyrazine
6. 5h-pyrrolo[2,3-b]pyrazine, 2-bromo-5-[(4-methylphenyl)sulfonyl]-
7. Schembl1536030
8. Dtxsid40680926
9. 2-bromo-5-(4-methylbenzenesulfonyl)-5h-pyrrolo[2,3-b]pyrazine
10. Amy13923
11. Bcp30870
12. Zinc40448943
13. Akos015919870
14. Cs-w009203
15. Ds-0650
16. Ac-31350
17. Da-26771
18. Sy046042
19. Ft-0712655
20. A857696
21. 2-bromo-5-(toluene-4-sulfonyl)-5h-pyrrolo[2,3-b]pyrazine
22. 2-bromo-5-(4-methylbenzene-1-sulfonyl)-5h-pyrrolo[2,3-b]pyrazine
23. 2-bromo-5-[(4-methylphenyl)sulfonyl]-5h-pyrrolo[2,3-b]pyrazine
Molecular Weight | 352.21 g/mol |
---|---|
Molecular Formula | C13H10BrN3O2S |
XLogP3 | 2.9 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 2 |
Exact Mass | 350.96771 g/mol |
Monoisotopic Mass | 350.96771 g/mol |
Topological Polar Surface Area | 73.2 Ų |
Heavy Atom Count | 20 |
Formal Charge | 0 |
Complexity | 445 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer.